Articles tagged with Leukemia
A groundbreaking clinical trial has shown that exercise can significantly improve symptoms of fatigue and depression, increase cardiovascular endurance, and maintain quality of life for adult leukemia patients undergoing treatment. The study demonstrated a substantial reduction in total fatigue and depression scores, as well as improve...
Researchers at Tel Aviv University have discovered a novel treatment for children with high-risk leukemia, leveraging a similar mutation linked to Down syndrome and polycythemia vera in adults. The JAK2 inhibitor offers promise as an alternative to chemotherapy, potentially reducing toxicity costs.
Researchers at MGH identified a chromosomal abnormality that leads to acute lymphoblastic leukemia (ALL) in children. The mutation affects hematopoietic stem cells and can lead to years-later cancer development.
Janet Davison Rowley's work established cancer as a genetic disease through discoveries of recurrent chromosomal abnormalities in leukemias and lymphomas. Her findings revolutionized how cancer is understood and treated, leading to more precise diagnoses and effective treatments.
A new study has identified a key protein receptor responsible for tumor cells invading the brain and spinal cord in childhood leukemia. The finding may lead to new drugs that block this receptor and reduce the risk of relapse in some leukemia patients.
Researchers at Mayo Clinic have found that patients with chronic lymphocytic leukemia (CLL) can tolerate high doses of green tea extract EGCG, leading to a significant reduction in lymphocyte count. The study also showed that many participants experienced regression of CLL symptoms, particularly those with enlarged lymph nodes.
The Cole Foundation has pledged $2.5 million to support up-and-coming researchers in pediatric leukemia research at the University of Montreal, McGill University, and the Institut Armand-Frappier. This investment will create new grants, awards, a cell bank, and fellowships to accelerate the fight against pediatric leukemia.
Researchers have pinpointed a new class of gene mutations that identify cases of childhood acute lymphoblastic leukemia with a high risk of relapse and death. The discovery suggests specific drugs could treat this subtype, building on previous studies hinting at kinases' role in the disease.
The Shilatifard Lab has provided new insight into H3K4 methylation, a crucial activity associated with MLL protein and chromosomal translocations. The study sheds light on how this process contributes to the development of aggressive infant acute leukemias.
A retrospective study of 2,854 Italian patients with MS found leukemia occurred in .74% of those treated with mitoxantrone, significantly higher than previously reported rates. The study highlights the need for careful hematological follow-up to check for acute leukemia.
Researchers have discovered that biphosphonates can prevent radiation-induced leukemia in laboratory mice, with 75% of treated mice developing the disease compared to 100% in untreated mice. The study suggests that these compounds may have a general effect on leukemia associated with causes other than radiation.
Scientists discovered a potential new biomarker, PDE7B, to predict the aggressiveness of chronic lymphocytic leukemia (CLL). High levels of PDE7B in white blood cells indicate aggressive CLL and need immediate treatment.
Researchers discovered the JunB gene's role in regulating hematopoietic stem cells, which produce blood cells. The study suggests that JunB can help prevent leukemia by limiting cell proliferation and differentiation.
Researchers identify LIPG gene mutations that result in elevated HDL-C levels, potentially increasing cardiovascular risk. Meanwhile, a new study suggests intermittent IL-7 therapy may boost CD4+ T cell counts in HIV-infected patients.
A study led by St. Jude Children's Research Hospital identified mutations in the IKZF1 gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). The findings suggest that this genetic marker could be used to tailor treatment intensity and improve patient outcomes.
A study by researchers from the University of Kentucky found that grape-seed extract induces apoptosis in leukemia cells by activating the JNK pathway, leading to cell cycle regulation and death. The extract has shown promise as a potential agent for preventing or treating hematological malignancies.
Leukemia takes over bone marrow niches, crowding out healthy stem cells. Blocking cancer cell chemical signals could help protect stem cells and improve treatment strategies. Researchers develop approach to blunt leukemia's effect on stem cells, potentially boosting immune system response.
Researchers discovered the MLL-AF4 protein binds to over 169 genes in cancer cells, hijacking blood stem cell machinery and causing cancerous cell division. This understanding may lead to new drug targets for treating mixed-lineage leukemia.
Two REVLIMID Phase II studies showed significant activity and tolerability in previously untreated CLL patients, achieving response rates of 52% and 96% with manageable side effects. The studies also indicated that continued treatment can improve response rates.
Researchers at M.D. Anderson Cancer Center report encouraging results from clinical trials of second-generation CML drugs nilotinib and dasatinib. These drugs have shown higher complete cytogenetic response rates compared to the frontline medication imatinib, with some patients achieving responses faster than ever seen before.
In a phase II clinical trial, lenalidomide demonstrated activity against chronic lymphocytic leukemia in elderly patients. The drug showed a favorable toxicity profile and achieved significant responses, including partial response in 54% of patients.
Four studies showcase treatment advances in blood cancers, including improved progression-free survival for patients with relapsed or refractory chronic lymphocytic leukemia. A new tumor suppressor gene is also discovered in patients with myeloproliferative disorders.
Novel treatments, including fostamatinib disodium, have shown significant clinical activity in treating leukemia and lymphoma. The study found improved response rates and prolonged stable disease in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Men who survived childhood leukemia treatment into adulthood have lower bone mineral density, increasing their risk of osteoporosis. The study found that male survivors were more likely than female survivors to have weaker bones, and shorter individuals also faced higher risks.
Researchers at UCSD have discovered a novel drug target, phosphodiesterase 7B (PDE7B), for treating chronic lymphocytic leukemia (CLL). Blocking PDE7B increases cAMP levels and causes CLL cells to undergo programmed cell death.
Researchers identified two genes that sensitize lymphoid progenitor cells to the effects of aging and confer resistance to leukemogenesis. These genes regulate cell cycle progression and mediate senescence and tumor suppression in aged cells.
A recent study published in Cancer Cell reveals a potential therapeutic approach for MLL-AF4 leukemias, a subtype of acute lymphoblastic leukemia that accounts for 70% of infant cases. By inhibiting the histone-modifying enzyme DOT1L, researchers hope to reverse cancer-promoting genes and improve treatment outcomes.
Researchers at Stanford University School of Medicine have developed a new diagnostic test that can identify rare leukemias in hours instead of weeks. The test uses cell-signaling pathways to decipher potentially dangerous molecular conversations, offering a more reliable assessment of risk and potential treatment options.
Researchers at Stanford University School of Medicine have discovered a novel 'double agent' role for glycogen synthase kinase 3 (GSK3) in regulating cell growth. Inhibiting GSK3 combats leukemias caused by mutated MLL genes, which account for five to 10 percent of child and adult leukemias.
Advances in treatment have led to increased long-term survival for US children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma. Period analysis reveals improved survival rates between 1990 and 2004, with projections suggesting continued progress through molecularly targeted therapies.
Researchers explore new treatments for psoriasis, revealing a potential therapeutic option in AEB071, while cautioning further clinical trials are needed. Additionally, studies uncover the reasons behind gene therapy complications in SCID patients, shedding light on insertional oncogenesis and acquired somatic mutations.
Researchers discover that Angiocidin can differentiate leukemia cells into a normal, macrophage-like phenotype, making them susceptible to chemotherapy treatment. The protein also stimulates the immune system by up-regulating genes characteristic of immune cells.
Research by VIB-K.U.Leuven scientists finds that location in cell affects carcinogenicity of NUP214-ABL1 protein, a kinase linked to T-cell acute lymphoblastic leukemia. This discovery opens new avenues for targeted therapies and potential treatment approaches.
Researchers found that LYN kinase activation is associated with imatinib resistance in CML patients, a mechanism not explained by BCR-ABL mutations. Blocking LYN kinase restores imatinib responsiveness and triggers cell death.
Researchers have developed a mathematical model that predicts optimal timing for a cancer vaccine in CML patients based on their immune response, which may lead to a cure. The model suggests boosting the immune system at a specific time when it starts weakening can provide a strong stimulation to combat leukemia cells.
A new mathematical model could lead to personalized vaccines for CML patients, strengthening the immune system during its weakest point. The study uses data from four years of imatinib therapy and recommends 'cancer vaccines' to combat drug resistance.
A Phase 2 clinical trial of GCS-100, a polysaccharide targeting galectin-3, demonstrates apoptosis induction and reduced leukocyte counts in relapsed CLL patients. The treatment was generally well tolerated with mild-to-moderate adverse events.
Researchers have identified a combination of novel anti-cancer compounds that can kill chronic myelogenous leukemia cells previously resistant to conventional therapy. The combination involves a Bcr/Abl kinase inhibitor and a histone deacetylase inhibitor, which work together to induce programmed cell death in CML cells.
Researchers at UCLA identified a type of leukemia stem cell and uncovered the genetic mechanisms that cause normal blood stem cells to become cancerous. This discovery may lead to new therapies targeting these stem cells, potentially curing certain cancers.
The study found that a combination of genetic mutations, including the deletion of gene IKZF1, can initiate most cases of an aggressive form of acute lymphoblastic leukemia. The researchers also identified cooperation between these genetic lesions and BCR-ABL1 expression.
Long-term childhood cancer survivors, especially those treated with radiation therapy, experience excess health problems and poor socioeconomic outcomes. The study found that survivors are more likely to have chronic medical conditions, mental health issues, and functional impairment compared to their siblings.
Researchers have identified a crucial role for antibodies in protecting against nontyphoidal strains of Salmonella bacteria, which causes fatal infections in African children. Meanwhile, a study on HOXB4 gene therapy found that early precursors can cause leukemia in large animals, highlighting the need for extreme caution in human trials.
Researchers at UCSD developed a gene therapy protocol that successfully activated the immune system in six patients with chronic lymphocytic leukemia. The protocol introduced a gene with potential to activate an immune response and resulted in the production of antibodies reacting against leukemia cells.
Researchers at University of Texas M.D. Anderson Cancer Center report promising early results for bosutinib in patients with chronic myelogenous leukemia (CML) who have developed resistance to frontline therapy. The drug has shown good efficacy and low toxicity, particularly when compared to other tyrosine kinase inhibitors.
A recent survey reveals a significant gap in knowledge among primary care physicians regarding rare blood cancers like leukemia and lymphoma. The findings emphasize the importance of education and referrals to specialists in improving patient survival rates. As long-term cancer survivors, patients are at risk of developing second cance...
A retrospective study found a link between erythropoiesis-stimulating agents and leukemic transformation in primary myelofibrosis patients. The research confirmed clinical and laboratory variables associated with leukemia development, including specific treatments that increased the risk of leukemic transformation.
Two drugs, dasatinib and nilotinib, are showing promising results as frontline therapy for newly diagnosed CML patients with high complete cytogenetic response rates of approximately 90% at 6 months. The treatments target a greater variety of genetic variations than imatinib, which has increased the 5-year survival rate for CML patient...
A peptide vaccine for leukemia improved event-free survival by 8.7 months compared to non-responders, with 36% of responders experiencing complete cytogenetic remission. The vaccine targets cancer cells and induces a specific immune response in patients with HLA-A2
Meis1 is required for maintaining leukemia stem cell properties in MLL leukemia, including self-renewal and differentiation arrest. The study provides new insights into the genetic underpinnings of MLL leukemogenesis.
A new study by Dartmouth Medical School researchers has identified a crucial pathway for blood stem cell turnover, which could lead to novel strategies for treating rare and aggressive infant leukemia. The research reveals that the Mixed Lineage Leukemia (MLL) gene plays an essential role in maintaining adult blood cells.
Researchers at the University of Texas M. D. Anderson Cancer Center found that congestive heart failure is rare among leukemia patients taking imatinib. Only 22 out of 1,276 patients developed symptoms that could be caused by heart failure, and most had underlying medical conditions that also contributed to their condition.
A study by St. Jude Children's Research Hospital reveals the loss of Arf gene and BCR-ABL mutation leaves cells vulnerable to growth-enhancing environment of bone marrow, promoting immunity to anti-leukemia drug imatinib.
Acute lymphoblastic leukemia patients with Philadelphia chromosome (Ph+) experience poor response to imatinib due to emerging drug-resistant clones. Research reveals signals from the bone marrow microenvironment can sustain viability of Ph+ ALL cells, enabling rapid resistance development.
Researchers discovered that an experimental multiple sclerosis drug, fingolimod, may also help patients with certain lethal forms of leukemia. The study found that the drug prevents cancer cell development and kills leukemia cells in mouse models, suggesting a promising new approach for treating resistant cases.
Researchers at the University of Pennsylvania have developed a mathematical formula to assess disease cluster risk, providing an exact probability calculation in under five seconds. The formula was used to investigate two disease clusters, one likely due to chance and the other possibly caused by a common environmental factor.
A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia by targeting the CD37 protein on leukemia cells and triggering self-destruction. The agent works equally as well as rituximab, a commonly used treatment for CLL.
The Damon Runyon Cancer Research Foundation has renewed its investment in young clinical cancer investigators, providing $2.25 million to support the development of their cancer research programs. Five new awardees will receive funding to investigate various types of cancer, including leukemia, lymphoma, and esophageal cancer.
Researchers have confirmed that arsenic trioxide significantly improves patient survival in newly diagnosed acute promyelocytic leukemia (APL) patients. Nearly 600 patients participated in a six-year phase III study, showing improved disease-free rates and longer survival compared to standard chemotherapy alone.
A Phase II clinical trial at M.D. Anderson Cancer Center found dasatinib achieves complete cytogenetic response in 77-95% of newly diagnosed CML patients, compared to historical data on imatinib. The rapid response rate suggests dasatinib may be more effective as a first-line treatment for CML.
A new study identified a genetic mutation in the DAPK1 gene that increases the risk of chronic lymphocytic leukemia. The mutation reduces the gene's protective activity and can be followed by a chemical change called DNA methylation, which leads to leukemia.